Across TCGA pan-cancer cohorts, MS4A3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MS4A3 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MS4A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MS4A3 expression acts as an unfavorable survival marker.
CESC, BLCA, and SKCM are the cancer types where MS4A3 Mutation most reproducibly stratifies survival.